Inotropic Effects of Gaseous Transmitters in Isolated Rat Heart Preparation

@article{Porokhya2012InotropicEO,
  title={Inotropic Effects of Gaseous Transmitters in Isolated Rat Heart Preparation},
  author={M. V. Porokhya and Denis V. Abramochkin and A. A. Abramov and Vladislav S Kuzmin and Galina S. Sukhova},
  journal={Bulletin of Experimental Biology and Medicine},
  year={2012},
  volume={153},
  pages={856 - 858}
}
We studied the effects of carbon monoxide and sodium hydrosulfide, hydrogen sulfide donor, on contractile activity of the left ventricle in Langendorf-perfused isolated rat heart. Carbon monoxide 5×10−5 M significantly accelerated sinus rhythm and left-ventricular pressure wave growth and decay. To the contrary, negative inotropic and chronotropic effects were observed at higher concentrations of carbon monoxide (10−4, 3×10−4 M). Sodium hydrosulfide (10−4-4×10−4 M) decreased all the parameters… 

Analysis of decreases in systemic arterial pressure and heart rate in response to the hydrogen sulfide donor sodium sulfide.

The hypotensive and bradycardic effects of H2S can be dissociated, as shown with cardiac pacing experiments, and cardiovascular responses observed in spontaneously hypertensive rats were more robust than those in Sprague-Dawley rats.

Hydrosulfide attenuates acute myocardial ischemic injury through the glycogen synthase kinase-3β/β-catenin signaling pathway

It is suggested that hydrosulfide exerts cardioprotective effects against AMI-induced apoptosis through the GSK-3β/β-catenin signaling pathway.

Boosting endogenous production of vasoprotective hydrogen sulfide via supplementation with taurine and N-acetylcysteine: a novel way to promote cardiovascular health

Physiological concentrations of H2S can oppose atherogenesis, ameliorate systemic and pulmonary hypertension, as well as protect the heart subjected to pressure overload, endoplasmic reticulum (ER) stress or adrenergic overstimulation.

Phosphinodithioate and Phosphoramidodithioate Hydrogen Sulfide Donors.

The phosphorodithioate GYY4137 has been proposed as "slow-release" H2S donors and has shown promising efficacy in cellular and animal model diseases such as hypertension, sepsis, atherosclerosis, neonatal lung injury and cancer, however, H 2S generation is inefficient necessitating its use at high concentrations/doses.